血清类胰岛素生长因子Ⅰ与前列腺癌的危险性——一组回顾性研究

目的 :研究血清类胰岛素生长因子Ⅰ (Insulin -likegrowthfactor - 1,IGF -Ⅰ )与前列腺癌的关系。方法 :采用免疫放射量度分析法 (IRMA)测定 30例前列腺癌患者血清IGF -Ⅰ水平 ,并以 30例健康组以及30例良性前列腺增生 (BPH)患者作对照。结果 :前列腺癌组血清IGF -Ⅰ含量显著上升 (148± 49.6 μg/L) ,与BPH(91.0± 32 .8μg/L)及健康组 (10 5± 2 5 .6 μg/L)差异有显著性 (均为P <0 .0 0 1)。BPH组血清IGF -Ⅰ含量与健康组比较差异无显著性 (P >0 .0 5 ) ;前列腺癌患者各期血清IGF -Ⅰ含量比较差异无显著性 (P >0 .0 5 ) ;IGF-Ⅰ与BPH无关 ,其水平升高增加前列腺癌的危险性 ,与健康组相比较 ,高IGF -Ⅰ水平患者前列腺癌的相对危险度 (OR)为 11.2 3,95 % ,可信区间为 3.0 9～ 40 .7,前列腺癌患者与健康组之间有统计学意义 (P <0 .0 0 1)。结论 :提示IGF -Ⅰ可能增加患前列腺癌的危险性。     

肝硬化患者血清IGF-Ⅰ、IGFBP-3检测的临床意义

目的：探讨肝硬化患者血清胰岛素样生长因子（IGF—Ⅰ）及其结合蛋白（IGFBP-3）检测的临床意义。方法：应用免疫放射分析测定35例肝硬化患者（肝硬化组）,25例急性肝炎患者（肝炎组）,35例健康人（对照组）血清IGF—Ⅰ、IGFBP-3水平,比较两者在3组中的浓度不同及在肝硬化不同Child—Pugh级别者中的变化。结果：血清IGF—Ⅰ、IGFBP-3水平肝硬化组显著低于急性肝炎组和正常对照组（P〈0．01）,且在肝硬化组不同Child—Pugh分级中呈逐渐下降。而急性肝炎组与正常对照组之间无显著差异（P〉0．05）。结论：IGF—Ⅰ、IGFBP～3水平下降是发生肝硬化的重要指标之一。联合检测IGF—Ⅰ、IGFBP-3水平可用来综合评估肝硬化患者的肝功能状态。     

血tPSA、cPSA、IGF-I联检对前列腺疾病诊断的临床价值

目的：探讨联检血清前列腺特异性抗原（tPSA）、复合前列腺特异性抗原（cPSA）、胰岛素样生长因子-I（IGF—I）含量及cPSA／tPSA比值对前列腺疾病诊断的临床价值。方法：分别采用磁微粒免疫化学发光法（ICLMA）和免疫放射分析（IRMA）对41例前列腺癌（PCa）、60例前列腺增生（BPH）患者和55例正常对照者进行tPSA、cPSA、IGF—I定量检测和计算cPSA／tPSA比值并比较分析。结果：PCa患者血清中tPSA、cPSA、IGF—I水平明显高于BPH组和正常对照组（P〈0．01）;BPH、PCa两组患者各项检测指标在“灰色区域”上分布差异有显著性（P〈0．01）;以tPSA〉4ng／ml、cPSA〉3．6ng／ml、IGF—I〉150和cPSA／tPSA〉0．74作为筛选PCa的临界值,其临床灵敏度、特异度、阳性预测值、阴性预测值分别为88．6％、84．9％、83．0％、90．0％。结论：联合使用tPSA、cPSA、cPSA／tPSA和IGF—I指标进行PCa的筛选,其临床诊断概率优于各单一指标,且对早期PCa的诊断和BPH的区别有重要的临床价值。     

自身免疫性甲状腺疾病胰岛素样生长因子及其结合蛋白的改变

为探讨胰岛素样生长因子 (IGF )、胰岛素样生长因子结合蛋白 (IGFBP )在自身免疫性甲状腺疾病 (AITD )中的变化及其影响 ,本研究检测了 5 6例AITD患者与 2 4例正常对照血清IGF 1、IGFBP 1～ 3及甲状腺功能 ,发现IGF 1在GD、HT与GD控制组明显低于正常对照 (P <0 0 1) ,IGFBP 1、IGFBP 2在GD组明显高于正常对照 (P <0 0 1,0 0 5 ) ,IGFBP 3在HT组明显低于正常对照 (P <0 0 5 ) ;IGF 1与甲状腺激素间无相关 ,IGFBP 1～ 3均与TT4相关 (r =0 34、 0 38、 0 31;P <0 0 5 )。提示机体甲状腺激素、免疫状态均可能影响IGF、IGFBP水平 ,而后者有可能参与调节AITD的进程。     

前列腺癌患者血清fPSA与IGF-1联检的临床价值

目的 :探讨血清游离前列腺特异性抗原 (fPSA)和胰岛素生长因子 - 1(IGF - 1)联检对前列腺癌早期诊断的价值。方法 :分别测定正常对照组、前列腺增生组及前列腺癌组的fPSA和IGF - 1水平 ,并对结果进行组间t检验分析。结果 :前列腺增生及前列腺癌组的fPSA和IGF - 1水平均显著高于正常对照组 (P <0 0 5 ) ,且统计分析发现fPSA、IGF - 1及二者联检对前列腺癌诊断的阳性率分别为 83 3%、79 2 %、95 8%。结论 :联检fPSA和IGF - 1水平能提高对前列腺癌检出的敏感性 ,是前列腺癌筛查的有效手段。     

血清cPSA、IGF-1和TGFα联合检测对前列腺癌诊断价值的探讨

探讨联合检测血清结合前列腺特异抗原（ePSA）、胰岛素样生长因子1（IGF-1）、转化生长因子α（TGFα）对前列腺癌（PCa）的诊断价值。采用磁微粒免疫化学发光法（ICLMA）、IRMA和RIA，对46例PCa组、64例良性前列腺增生（BPH）组和73名健康男性对照组血清cPSA、IGF-1和TGFα进行测定，并动态观察37例PCa患者术后第1个月、3个月和6个月cPSA、IGF-1、TGFα含量。结果表明：PCa组血清cPSA、IGF-1和TGFα含量明显高于BPH组和对照组，有显著性差异（P〈0．05）。IGF-1在PCa发展中有增高的趋势，但PCa临床各期之间无显著性差异（P〉0．05）。cPSA、TGFα在PCa各期之间有显著性差异（P〈0．05）。因此联合检测cPSA、IGF-1和TGFα对PCa的预测、诊断及疗效监测有一定意义，同时cPSA和TGFα可为PCa临床分期提供依据。     

IGF—1和胰岛素对成骨细胞功能影响的研究进展

胰岛素样生长因子—1(IGF—1)是一类既具有促进细胞分化和增殖活性又具有胰岛素样作用的多肽。IGF—1与胰岛素原有60％的结构同源性，对小鼠、大鼠和人的成骨细胞的研究结果显示：IGF—1和胰岛素可通过促进骨祖细胞及成骨样细胞的增殖和分化等多种机制而发挥保护骨量的作用，IGF—1和胰岛素的作用受IGF结合蛋白(IGFBP)、激素和细胞因子的调节。     

子宫内膜异位症患者血清中胰岛素样生长因子Ⅰ(IGF1)水平变化的意义

目的探索子宫内膜异位症患者血清IGF1水平变化与子宫内膜异位症发病的关系。方法采用双抗体夹心ABC ELISA法测定36例子宫内膜异位症患者及24例健康妇女IGF1水平。结果(1)子宫内膜异位症组血清IGF1水平为(284.4±86.6)ng/m l,对照组血清IGF1水平为(138.2±74.1)ng/m l。子宫内膜异位症组血清IGF1水平高于对照组血清IGF1水平,两组比较,差异有显着性(P<0.05)。(2)两组妇女分别进行增生期与分泌期血清中IGF1水平比较,正常组妇女增生期与分泌期血清中IGF1水平比较,差异无显著性(P>0.05)。子宫内膜异位症组妇女增生期与分泌期血清中IGF1水平比较,差异无显着性(P>0.05)。结论血清中IGF1水平变化与子宫内膜异位症的发病密切相关。     

原发性高血压患者血清IGFⅡ和ADM测定及其临床意义

目的 :探讨原发性高血压患者血清胰岛素样生长因子Ⅱ (IGFⅡ )和肾上腺髓质素 (ADM)变化及其临床意义。方法 :用放射免疫分析测定了 6 2例原发性高血压 (EH)患者和 4 0例非高血压患者的血清IGFⅡ和ADM水平 ,并进行对照统计分析。结果 :EH组血清IGFⅡ和ADM水平均显著高于对照组 (p <0 0 1) ,相互间呈显著正相关 (p <0 0 5 ) ,且均与平均动脉压成显著正相关 (p<0 0 5 ) ,与体重指数无相关性意义。在Ⅰ、Ⅱ、Ⅲ期组间 ,血清ADM水平依次递增 (方差F检验 ,p <0 0 5 ) ,且Ⅲ期组显著高于Ⅰ期组 (p <0 0 1) ,伴心脑肾并发症组血清ADM水平也显著高于无并发症组 (p <0 0 5 ) ;血清IGFⅡ水平则无统计学意义。结论 :EH患者血清IGFⅡ和ADM水平显著升高 ,相互间成正相关 ,且均与平均动脉压成正相关 ,随着病情进展 ,ADM有进一步升高趋势 ,但IGFⅡ则否     

冠心病患者血清胰岛素样生长因子Ⅱ测定及其意义

目的 :探讨冠心病 (CHD)患者血清胰岛素样生长因子Ⅱ水平的变化及其临床意义。方法 :采用放射免疫分析法测定了 6 8例CHD患者和 30例非冠心病患者的血清IGFⅡ水平 ,进行对照统计分析。结果 :CHD组血清IGFⅡ水平显著高于对照组 (t=5 5 0 6 ,p<0 0 1) ,合并急性心肌梗塞组血清IGFⅡ水平显著高于无合并组 (t=2 2 5 4 ,p <0 0 5 )。出现心力衰竭组血清IGFⅡ与无心力衰竭组无显著差异 (t=0 92 1,p >0 0 5 )。住院死亡组血清IGFⅡ水平显著高于好转出院组 (t=2 4 0 2 ,p <0 0 5 )。结论 :CHD组血清IGFⅡ水平显著高于对照组 ,合并AMI组血清IGFⅡ水平显著高于无合并组 ,住院死亡组血清IGFⅡ水平显著高于好转出院组。     

Pituitary Insulin: Insulin-Like Growth Factors

Insulin-like growth factor (IGF)-I and IGF-II peptides as well as their mRNAs are produced in many organs, including the pituitary. Although IGF-I and IGF-II peptides are localized in endocrine cells of the anterior pituitary, IGF-I mRNA can be detected throughout the adenohypophysis, and IGF-II mRNA is abundant in intermediate and neural lobes. It is well-established that both circulating and intrinsic IGF-I are negative regulators of pituitary GH production. Other functions of intrinsic IGFs in normal and tumorous pituitary are just emerging. IGF-I may play a role in the stimulation of PRL synthesis and mediation of proliferative effects of estrogen on lactotroph. Compared with IGF-I, the function of IGF-II has not been clarified so far. The growth-promoting actions of IGFs are mediated by IGF-I receptor. The role of local and circulating IGFBPs in pituitary are not yet documented. IGFBPs in other tissues have inhibitory and stimulatory effects on IGFs, and can act independently from the IGFs as well. IGFs have been reported to promote cell proliferation in many tumors. However, the extent to which IGFs contribute to pituitary tumor development and growth remains obscure.     

Insulin-Like Growth Factor (IGF) and Bone

Bone is not only a rich source of a diverse group of growth factors, but is also a very responsive tissue to such growth promoting agents. IGF-I and IGF-I1 are reported to be synthesized and retained in bone. While both IGF-I and IGF-II stimulate DNA, collagen, and noncollagenous protein synthesis in cultured calvariae, these explant cultures have quantitative differential sensitivities to these IGF's. In addition to the observed increase in collagen synthesis, collagen degradation decreased in calvariae treated with IGF-I or IGF-II.     

生长激素/IGF-1对认知功能的影响(综述)

1生长激素与IGF-1简介生长激素(Growth hormone,GH)主要由脑垂体分泌,可以促进脂肪酸代谢和氨基酸的吸收,以及DNA、RNA和蛋白质的合成。胰岛素样生长因子-1(Insulin-like growth factor-1,IGF-1),是一类介导合成代谢且具有GH样效应的细胞因子。血液中的IGF-1主要由肝脏合成,年龄、性别、营养状况、激素等多种因素都能影响血清IGF-1浓度。在众多激素中,GH对IGF-1的调节最重要。GH通过肝脏GH受体促进肝脏IGF-1的合成释放,而IGF-1反馈抑制垂体释放GH。在正常脑组织中存在GH和IGF-1以及它们的受体。IGF-1通过与IGF-1R结合…     

Somatomedin-1 (Recombinant Insulin-Like Growth Factor-1)

Insulin-like growth factor (IGF-1) is a polypeptide of 70 amino acids. The circulatory form of IGF-1 is synthesised in the liver. The metabolic activity of IGF-1 is regulated by 6 IGF-binding proteins (BPs), the most important being IGFBP-3. IGF-1 acts via its own receptor, which resembles that of insulin. It has been demonstrated that the effects of growth hormone (GH) on protein metabolism, including growth and the effect on nerve tissue versus trophic effects, are mediated by IGF-1, whereas these 2 hormones are antagonistic in their effects on insulin and some aspects of lipid metabolism. This paper reviews present knowledge on the physiological role of IGF-1 and clinical effects of recombinant IGF-1 (somatomedin-1). The biosynthesis of somatomedin-1 in 1986 enabled the initiation of clinical trials. Somatomedin-1 has many potential uses in the clinic. The most important is replacement therapy in primary IGF-1 deficiency, such as Laron syndrome (primary GH resistance or insensitivity) and in patients who have developed antibodies to hGH. In Laron syndrome, which is characterised by dwarfism, somatomedin-1 stimulates growth and increases muscle and bone mass, as well as normalising blood chemistry. In types 1 and 2 (insulin-dependent and non-insulin-dependent) diabetes mellitus, somatomedin-1 increases the sensitivity to insulin and improves glucose utilisation. Experimental studies indicate that IGF-1 has a role in nerve tissue metabolism, and in humans may contribute to healing of injured nerve tissue. Other current clinical trials using the anabolic properties of somatomedin-1 are studying its effect on osteoporosis, catabolic states (burns, post-operation, AIDS) and haematopoietic disorders. Adverse effects of somatomedin-1 appear to be related to overdosage. In conclusion, somatomedin-1 is an important hormone which has a promising role as replacement therapy and appears to have many other potential applications in the clinic.     

胰岛素样生长因子—Ⅰ在胎儿肝，肾等组织的分布

目的 研究胰岛素样生长因子（IGFs）对胎儿组织增殖和分化的作用。方法 应用免疫组化ABC法对16至24周胎龄肝、肾、肾上腺、脾、胸腺等ICF－I阳性细胞进行定位研究。结果 胎儿期内,以上器官中均有IGF－I阳性细胞存在,不同个体和器官其阳性细胞的数量、反应强弱和表达情况有差异。结论 在人胎发育过程中,这些器官组织均能表达IGF－I,对其增殖分化起着自分泌和旁分泌的作用。     

Insulin-Like Growth Factor 2: New Roles for a Known Molecule

Neuroscience and Behavioral Physiology - Insulin-like growth factor 2 (IGF2) is conventionally regarded as the main growth factor acting in the fetal body during pregnancy. Recent studies have...     

Treatment with Insulin-Like Growth Factor-1 Increases Chondrogenesis by Periosteum In Vitro

The repair of defects in articular cartilage with hyaline tissue that is resilient to wear is a challenging problem. Fibrocartilaginous tissue forms in response to injury through the articular surface and degenerates under mechanical load. Because periosteum contains cells, which are capable of synthesizing cartilage matrix proteins, it has been used to repair defects in articular surfaces. Treatment of periosteal grafts with growth factors, particularly those that elicit chondrocyte gene expression, may improve tissue regeneration. Gene expression by periosteal explants in vitro was measured. Expression of type II collagen and aggrecan mRNA was increased in response to treatment with IGF-I. Furthermore, IGF-I treatment caused an increase in type II collagen and aggrecan mRNA that was time and concentration dependent. The effect of short and long-term (continuous) incubations was compared to determine if a pretreatment could be used to condition a graft for subsequent surgical use. Short-term incubation in vitro with IGF-I followed by incubation without IGF-I was nearly as effective at increasing expression of type II collagen and aggrecan mRNA as incubation for the same length of time with IGF-I present continuously in the culture media. Treatment with IGF-I also produced cell clustering and nodule formation which are indicative of chondrogenesis. These results suggest that pretreatment with IGF-I in vitro may enhance the effectiveness of a graft to produce hyaline cartilage in vivo. Whether the cellular and molecular changes we have observed can lead to the formation of tissue that withstands the mechanical forces exerted by weight bearing remains to be determined.     

Immunohistochemical Localization of Components of the Insulin-Like Growth Factor-System in Human Deciduous Teeth

To investigate the occurrence of components of the insulin-like growth factor (IGF) system during the resorption process of shedding human deciduous teeth, we investigated sections of 13 decalcified and paraffin-embedded deciduous teeth immunohistochemically with antibodies against IGF-I and -II, six IGF binding proteins (IGFBPs 1-6) and the IGF receptors IGFIR and IGF2R. The teeth were in different stages of resorption and all showed reparative cementum formation. It was found that acellular extrinsic fiber cementum, reversal lines and reparative cellular intrinsic fiber cementum were immunoreactive for both IGFs and various IGFBPs. Therefore, in human deciduous teeth, all subgroups of cementum, but not dentine, may represent sources of components of the IGF system. Odontoclasts did not carry IGFs or the IGF1R, but IGFBPs and the IGF2R. Therefore, these cells, in contrast to osteoclasts, may not respond to IGFs, but may be involved in the release and sequestration of IGFs from cementum during the resorption process. In contrast to odontoclasts, cementoblasts and periodontal ligament (PDL) fibroblasts carried IGF1R. The influence of the IGF system on the function of these cells with respect to periodontal matrix turnover and cementogenesis is discussed. On the behalf of the IGFBP immunoreactivities found, the PDL extracellular matrix can be considered to be a reservoir for IGF system components, where binding proteins may regulate IGF distribution and activity.